ReviewFrontiers in microbiology2023
Advances in bacteriophage-mediated strategies for combating polymicrobial biofilms.
Review in Frontiers in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 39 citations in OpenAlex.
- A Lytic Bacteriophage Cocktail Attenuates Carbapenem-Resistant Klebsiella pneumoniae-Acinetobacter baumannii Mixed-Species Biofilms and Reshapes Transcriptional Responses.Microbial biotechnology · 2026Article
- Beyond Antibiotics: Harnessing Bacteriotherapy to Heal Chronic Lymphatic Filariasis Wounds.Probiotics and antimicrobial proteins · 2026Review
- Phage cocktails for the disinfection of carbapenem-resistant Klebsiella pneumoniae on high-touch surfaces in intensive care units.BMC microbiology · 2026Article
- Model-dependent efficacy of sequential phage-antibiotic-antifungal therapy against dual-species biofilms.Biofilm · 2026Article
- Two Worlds, One Battle: How Bacteria and Malignancies Converge on Drug Resistance.International journal of molecular sciences · 2026Review
- Phage-Microbiota Interactions in the Gut: Implications for Health and Therapeutic Strategies.Probiotics and antimicrobial proteins · 2026Review
- Biofilms in clinical infection: pathophysiology, diagnosis, and the evolving therapeutic landscape.Journal of clinical microbiology · 2026Review
- Genomic characterization of Pseudomonas aeruginosa infecting Abidjanvirus Lucjan.Molecular genetics and genomics : MGG · 2026Article
- Phage therapy for treatment of bacterial vaginosis.Archives of microbiology · 2026Review
- Precision Microbial Therapeutics for Infertility: Next-Generation Probiotics, Engineered Biologics and Translational Pathways.Microbial biotechnology · 2026Review
- Novel Koutsourovirus phages disrupt clinical multidrug-resistant Enterobacter cloacae biofilms: genomic and functional characterization.Folia microbiologica · 2026Article
- Virus Enhanced Microrobots for Biofilm Eradication.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Utilizing the effectiveness of phage cocktail to combat Shigella and Salmonella infections and their polymicrobial biofilm control activity.BMC microbiology · 2025Article
- Metagenomic analysis of viral communities in the polluted Varuna River reveals site-specific diversity patterns associated with environmental aspects.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Isolation and Characterization of A Novel Pbunavirus with Promising Antibiofilm Activity Against Pseudomonas Aeruginosa.Current microbiology · 2025Article
- Biofilms Exposed: Innovative Imaging and Therapeutic Platforms for Persistent Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Innovative approaches to combat antibiotic resistance: integrating CRISPR/Cas9 and nanoparticles against biofilm-driven infections.BMC medicine · 2025Review
- Polymicrobial Biofilms: Interkingdom Interactions, Resistance and Therapeutic Strategies.Microbial biotechnology · 2025Review
- Biofilms and oral health: nanotechnology for biofilm control.Discover nano · 2025Review
- [Potential of bacteriophage therapy in Germany: evidence and clinical relevance].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacteria and fungi tend to coexist within biofilms instead of in planktonic states. Usually, such communities include cross-kingdom microorganisms, which make them harder to remove from abiotic surfaces or infection sites. Additionally, the produced biofilm matrix protects embedded microorganisms from antibiotics, disinfectants, or the host immune system. Therefore, classic therapies based on antibiotics might be ineffective, especially when multidrug-resistant bacteria are causative factors. The complexities surrounding the eradication of biofilms from diverse surfaces and the human body have spurred the exploration of alternative therapeutic modalities. Among these options, bacteriophages and their enzymatic counterparts have emerged as promising candidates, either employed independently or in synergy with antibiotics and other agents. Phages are natural bacteria killers because of mechanisms of action that differ from antibiotics, phages might answer worldwide problems with bacterial infections. In this review, we report the attempts to use bacteriophages in combating polymicrobial biofilms in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.